TITLE

Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?

AUTHOR(S)
Walensky, Rochelle P.; Hirsch, Martin S.
PUB. DATE
October 2015
SOURCE
Clinical Infectious Diseases;10/1/2015, Vol. 61 Issue 7, p1196
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The authors discuss the confusion among physicians over when to start antiretroviral therapy (ART) in cases of in human immunodeficiency virus (HIV) infections. Topics discussed include association of death rates with deferred ART, public health advantages of early ART, and the benefit of early ART and early antituberculosis chemoprophylaxis.
ACCESSION #
109481978

 

Related Articles

  • Differing indications. Seid, Cherinet // CMAJ: Canadian Medical Association Journal;9/1/2009, Vol. 181 Issue 5, pE85 

    The article discusses the developments in the treatment of people having HIV and AIDS in Ethiopia. It notes there are centres in Addis Ababa, the capital city, offering HIV care which includes highly-active antiretroviral treatment. According to the article, the establishment of highly-active...

  • Early Use of Antiretrovirals May Reduce HIV Transmission. Norman, Kayda // Applied Clinical Trials;Jun2011, Vol. 20 Issue 6, p17 

    The article discusses the findings of a study on a clinical trial known as the HPTN 052 in relation to the early use of oral antiretroviral therapy (ART). It states that the early use of ART may reduce the likelihood that a person with human immunodeficiency virus (HIV) will pass the virus to...

  • Current perspectives in HIV post-exposure prophylaxis. Sultan, Binta; Benn, Paul; Waters, Laura // HIV/AIDS - Research & Palliative Care;2014, Vol. 6, p147 

    The incidence of human immunodeficiency virus (HIV) infection continues to rise among core groups and efforts to reduce the numbers of new infections are being redoubled. Post-exposure prophylaxis (PEP) is the use of short-term antiretroviral therapy (ART) to reduce the risk of acquisition of...

  • Loss of correlation between HIV viral load and CD4 + T-cell counts in HIV/HTLV-1 co-infection in treatment naïve Mozambican patients. Bhatt, N. B.; Gudo, E. S.; Semá, C.; Bila, D.; Di Mattel, P.; Augusto, O.; Garsia, R.; Jani, I. V. // International Journal of STD & AIDS;Dec2009, Vol. 20 Issue 12, p863 

    Summary: Seven hundred and four HIV-1 /2-positive, antiretroviral therapy (ART) naïve patients were screened for HTLV-1 infection. Antibodies to HTLV-1 were found in 32/704 (4.5%) of the patients. Each co-infected individual was matched with two HIV mono-infected patients according to World...

  • Experiences and Perceptions of Patients with 100% Adherence to Highly Active Antiretroviral Therapy: A Qualitative Study. Sidat, Mohsin; Fairley, Christopher; Grierson, Jeffrey // AIDS Patient Care & STDs;Jul2007, Vol. 21 Issue 7, p509 

    A decade has passed since the introduction of highly active antiretroviral therapy (HAART) as standard of care for HIV/AIDS patients. The success of HAART is largely dependent on almost 100% adherence to it. In this study our primary aim was to understand from patients' own perspectives and...

  • Evaluation of the Efficiency of Patient Flow at Three HIV Clinics in Uganda. Wanyenze, Rhoda K.; Wagner, Glenn; Alamo, Stella; Amanyire, Gideon; Ouma, Joseph; Kwarisima, Dalsone; Sunday, Pamella; Wabwire-Mangen, Fred; Kamya, Moses // AIDS Patient Care & STDs;Jul2010, Vol. 24 Issue 7, p441 

    With dramatic increases in antiretroviral therapy (ART) provision, many clinics in sub-Saharan Africa are congested, but little attention has focused on the efficiency of clinics. Between April and June 2008, we conducted a time-and-motion study to assess patient flow at three HIV clinics in...

  • Earlier start for HIV treatment indicated.  // Clinical Advisor;Jun2009, Vol. 12 Issue 6, p15 

    The article reports on the reduction of mortality risks by 94% of HIV patients if physicians in the U.S. start antiretroviral therapy when CD4 antigens counts are as high as 500 cells/uL. It notes that such advice was formulated from data based on older medications that produced more side...

  • Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. Deeks, Steven G.; Gange, Stephen J.; Kitahata, Mari M.; Saag, Michael S.; Justice, Amy C.; Hogg, Robert S.; Eron, Joseph J.; Brooks, John T.; Rourke, Sean B.; Gill, M. John; Bosch, Ronald J.; Benson, Constance A.; Collier, Ann C.; Martin, Jeffrey N.; Klein, Marina B.; Jacobson, Lisa P.; Rodriguez, Benigno; Sterling, Timothy R.; Kirk, Gregory D.; Napravnik, Sonia // Clinical Infectious Diseases;11/15/2009, Vol. 49 Issue 10, p1582 

    Background. Although combination antiretroviral therapy continues to evolve, with potentially more effective options emerging each year, the ability of therapy to prevent multiple regimen failure and mortality in clinical practice remains poorly defined. Methods. Sixteen cohorts representing...

  • Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods.  // BMC Public Health;2012, Vol. 12 Issue 1, p296 

    The article presents the findings of a research conducted on examining the risk of HIV transmission in a person on ART. It mentions that this PARTNER study is an international and observational study taking place from 2010 to 2014, in which HIV serodifferent partnerships who at enrolment...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics